Product Name
F11, Blocking Peptide
Full Product Name
F11 Peptide - C-terminal region
Product Gene Name
F11 blocking peptide
[Similar Products]
Product Synonym Gene Name
FXI; MGC141891[Similar Products]
F11 peptide (MBS3239980) is used for blocking the activity of F11 antibody (MBS3215064)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence
RHLCGGSIIG NQWILTAAHC FYGVESPKIL RVYSGILNQS EIKEDTSFFG
3D Structure
ModBase 3D Structure for P03951
Form/Format
Lyophilized powder
Preparation and Storage
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.
Other Notes
Small volumes of F11 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
F11 blocking peptide
This is a synthetic peptide designed for use in combination with anti-F11 Antibody, made
Target Description: This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality.
Product Categories/Family for F11 blocking peptide
Peptide
Applications Tested/Suitable for F11 blocking peptide
Western Blot (WB)
NCBI/Uniprot data below describe general gene information for F11. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000119
[Other Products]
NCBI GenBank Nucleotide #
NM_000128
[Other Products]
UniProt Primary Accession #
P03951
[Other Products]
UniProt Related Accession #
P03951[Other Products]
NCBI Official Full Name
coagulation factor XI isoform 1 preproprotein
NCBI Official Synonym Full Names
coagulation factor XI
NCBI Official Symbol
F11??[Similar Products]
NCBI Official Synonym Symbols
FXI; PTA
??[Similar Products]
NCBI Protein Information
coagulation factor XI
UniProt Protein Name
Coagulation factor XI
UniProt Synonym Protein Names
Plasma thromboplastin antecedent
Protein Family
Coagulation factor
UniProt Gene Name
F11??[Similar Products]
UniProt Synonym Gene Names
FXI; PTA??[Similar Products]
UniProt Entry Name
FA11_HUMAN
NCBI Summary for F11
This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality. [provided by RefSeq, Jul 2008]
UniProt Comments for F11
F11: Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Defects in F11 are the cause of factor XI deficiency (FA11D); also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome. It is a hemorrhagic disease characterized by reduced levels and activity of factor XI resulting in moderate bleeding symptoms, usually occurring after trauma or surgery. Patients usually do not present spontaneous bleeding but women can present with menorrhagia. Hemorrhages are usually moderate. Belongs to the peptidase S1 family. Plasma kallikrein subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Secreted, signal peptide; Secreted; EC 3.4.21.27; Protease
Chromosomal Location of Human Ortholog: 4q35
Cellular Component: extracellular space; membrane; plasma membrane; extracellular region
Molecular Function: heparin binding; protein binding; serine-type endopeptidase activity
Biological Process: positive regulation of fibrinolysis; proteolysis; blood coagulation; blood coagulation, intrinsic pathway; plasminogen activation
Disease: Factor Xi Deficiency
Research Articles on F11
1. Direct DNA sequencing analysis of the F11 genes revealed that all of the 14 patients had a F11 gene mutation. Eight different mutations were identified in the apple 1, apple 2 or serine protease domains, except one which was a splice site mutation. Six of the mutations were recurrent.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.